Tribe Technology set to deliver healthy pipeline of orders from Tier-One miners. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksOxford Biomedica Regulatory News (OXB)

Share Price Information for Oxford Biomedica (OXB)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 296.50
Bid: 297.50
Ask: 300.00
Change: -6.00 (-1.98%)
Spread: 2.50 (0.84%)
Open: 313.00
High: 313.50
Low: 296.50
Prev. Close: 302.50
OXB Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Interest In Shares

18 Dec 2007 13:35

Oxford Biomedica PLC18 December 2007 For Immediate Release 18 DECEMBER 2007 Oxford BioMedica PLC Identity of the issuer or the underlying issuer of existing shares to whichvoting rights are attached (ii): Oxford BioMedica PLC 2. Reason for the notification (please state Yes/No): ( ) An acquisition or disposal of voting rights: ( Yes ) An acquisition or disposal of financial instruments which may result in theacquisition of shares already issued to which voting rights are attached: ( ) An event changing the breakdown of voting rights: ( ) Other (please specify) : ( ) 3. Full name of person(s) subject to the notification obligation (iii): Prudential plc group of companies 4. Full name of shareholder(s) (if different from 3.) (iv): Prudential plc (parent company) M&G Group Limited (wholly owned subsidiary of Prudential plc) M&G Limited (wholly owned subsidiary of M&G Group Limited) M&G Investment Management Limited (wholly owned subsidiary of M&G Limited) M&G Securities Limited (wholly owned subsidiary of M&G Limited) The Prudential Assurance Company Limited (wholly owned subsidiary of Prudentialplc) 5. Date of the transaction (and date on which the threshold is crossed orreached if different) (v): 13 December 2007 6. Date on which issuer notified: 17 December 2007 7. Threshold(s) that is/are crossed or reached: 10% 8. Notified details: A: Voting rights attached to shares Class/type of shares if possible using Situation previous to the Triggeringthe ISIN CODE transaction (vi) Number of Number of shares voting Rights (viii)GB0006648157 52,943,339 52,943,339 Resulting situation after the triggering transaction (vii)Class/type of Number of Number of voting rights (ix) % of voting rightsshares if possible sharesusing the ISINCODE Direct Direct (x) Indirect (xi) Direct IndirectGB0006648157 54,488,025 54,488,025 10.19% B: Financial Instruments Resulting situation after the triggering transaction (xii)Type of Expiration Exercise/ Number of voting rights that may % offinancial Date Conversion be acquired if the instrument is votinginstrument (xiii) Period/Date exercised/ converted. rights (xiv) N/A N/A N/A N/A N/A Total (A+B) Number of % of voting voting rights rights 54,488,025 10.19% 9. Chain of controlled undertakings through which the voting rights and/or thefinancial instruments are effectively held, if applicable (xv): Registered Holder Holding % Prudential plc Total Notifiable Interest 54,488,025 10.19% Norturst Nominee Ltd A/C MHF01 134,616 Nortrust Nominee Ltd A/C MKK01 30,342,543 Nortrust Noms Ltd 124,000 PRUCLT HSBC GIS NOM (UK) PAC AC 18,750,368 PRUCLT HSBC GIS NOM (UK) PPL AC 5,134,498 M&G Group Limited 54,488,025 10.19% Norturst Nominee Ltd A/C MHF01 134,616 Nortrust Nominee Ltd A/C MKK01 30,342,543 Nortrust Noms Ltd 124,000 PRUCLT HSBC GIS NOM (UK) PAC AC 18,750,368 PRUCLT HSBC GIS NOM (UK) PPL AC 5,134,498 M&G Investment ManagementLimited 54,353,409 10.16% Nortrust Nominee Ltd A/C MKK01 30,342,543 Nortrust Noms Ltd 124,000 PRUCLT HSBC GIS NOM (UK) PAC AC 18,750,368 PRUCLT HSBC GIS NOM (UK) PPL AC 5,134,498 M&G Limited 54,488,025 10.19% Norturst Nominee Ltd A/C MHF01 134,616 Nortrust Nominee Ltd A/C MKK01 30,342,543 Nortrust Noms Ltd 124,000 PRUCLT HSBC GIS NOM (UK) PAC AC 18,750,368 PRUCLT HSBC GIS NOM (UK) PPL AC 5,134,498 M&G Securities Limited 30,477,159 5.70% Norturst Nominee Ltd A/C MHF01 134,616 Nortrust Nominee Ltd A/C MKK01 30,342,543 The Prudential AssuranceCompany Limited 23,886,866 4.46% PRUCLT HSBC GIS NOM (UK) PAC AC 18,750,368 PRUCLT HSBC GIS NOM (UK) PPL AC 5,134,498 Proxy Voting: 10. Name of the proxy holder: N/A 11. Number of voting rights proxy holder will cease to hold: N/A 12. Date on which proxy holder will cease to hold voting rights: N/A 13. Additional information: N/A 14. Contact name: Andrew Wood 15. Contact telephone number: 01865 783000 This information is provided by RNS The company news service from the London Stock Exchange
Date   Source Headline
21st Dec 20181:16 pmRNSDirector Dealings / Market Share Purchase
6th Dec 20184:11 pmRNSAxovant FDA meeting feedback
3rd Dec 20189:53 amRNSTotal Voting Rights
3rd Dec 20187:00 amRNSLonger term Kymriah efficacy and safety data
23rd Nov 201810:41 amRNSDirector Dealings
23rd Nov 20187:00 amRNSOxford Biomedica form digital framework initiative
9th Nov 20187:00 amRNSBlock listing application
1st Nov 20182:41 pmRNSTotal Voting Rights
25th Oct 20187:00 amRNSAxovant Doses First Patient with AXO-Lenti-PD
22nd Oct 20184:39 pmRNSDirector Dealings / Market Share Purchase
5th Oct 20187:00 amRNSDetails of alliance with Orchard Therapeutics
1st Oct 20189:41 amRNSTotal Voting Rights
24th Sep 201812:20 pmRNSDirector/PDMR Shareholding
20th Sep 201810:57 amEQSHardman & Co Research: Oxford BioMedica (OXB): Partnering strategy delivering profitability
13th Sep 20187:00 amRNSOxford BioMedica Interim Results
13th Sep 20187:00 amRNSOxford BioMedica further capacity expansion
3rd Sep 20189:18 amRNSTotal Voting Rights
28th Aug 20187:00 amRNSKymriah® receives European Commission Approval
22nd Aug 201811:58 amRNSDirector/PDMR Shareholding
15th Aug 20187:00 amRNSRNS notice of results OXB
14th Aug 20187:15 amEQSHardman & Co Research: Oxford BioMedica (OXB): Risk-sharing in cystic fibrosis gene-therapy
13th Aug 201810:55 amRNSDirector/PDMR Shareholding
13th Aug 201810:48 amRNSDirector/PDMR Shareholding
10th Aug 201811:39 amRNSPDMR Dealings / Market Share Sale
10th Aug 201811:36 amRNSDirector Dealings / Market Share Sale and Purchase
8th Aug 20182:45 pmRNSShare Options and LTIPs Granted
6th Aug 20187:02 amRNSPartnership for Cystic Fibrosis Gene Therapy
1st Aug 20189:53 amRNSTotal Voting Rights
23rd Jul 201812:54 pmRNSDirector Dealings / Market Share Purchase
2nd Jul 201810:25 amRNSDirectorate Change
2nd Jul 20189:47 amRNSTotal Voting Rights
29th Jun 20181:37 pmRNSKymriah receives positive CHMP opinion
25th Jun 20185:19 pmRNSHoldings in Company
22nd Jun 201812:05 pmRNSConfirmation of change of Auditor
22nd Jun 201812:03 pmRNSDirector Dealings / Market Share Purchase
21st Jun 20185:52 pmRNSHoldings in Company
14th Jun 20189:51 amEQSHardman & Co Research: Oxford BioMedica (OXB): Gene-therapy for Parkinson's: clinical progression
6th Jun 20187:00 amRNSOXB and Axovant Sciences Licence Agreement
4th Jun 20186:08 pmRNSDirectorate Change
1st Jun 20189:24 amRNSBlock Listing Return
1st Jun 20189:19 amRNSTotal Voting Rights
30th May 20184:23 pmRNSHoldings in Company
29th May 20181:21 pmRNSResult of General Meeting
29th May 20181:21 pmRNSResult of AGM
23rd May 20181:40 pmRNSDirector Dealings / Market Share Purchase
4th May 20187:00 amRNSProposed Share Capital Consolidation
2nd May 20187:00 amRNSKymriah receives FDA approval for DLBCL
1st May 20189:37 amRNSTotal Voting Rights
26th Apr 20183:33 pmRNSHolding(s) in Company
26th Apr 20187:30 amRNS2017 Annual Report and Accounts & AGM Notification

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.